- Home
- NVAX
NVAX
Novavax Inc.
as 02-04-2025 2:35pm EST
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | GAITHERSBURG |
| Market Cap: | 1.4B | IPO Year: | 1995 |
| Target Price: | $17.83 | AVG Volume (30 days): | 4.8M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.60 - $23.86 | Next Earning Date: | 02-26-2025 |
| Revenue: | $885,193,000 | Revenue Growth: | -15.68% |
| Revenue Growth (this year): | -24.92% | Revenue Growth (next year): | -23.03% |
Stock Insider Trading Activity of Novavax Inc. (NVAX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| YOUNG JAMES F | NVAX | Director | Dec 24 '24 | Sell | $8.24 | 10,000 | $82,208.00 | 57,160 | |
| King Rachel K. | NVAX | Director | Dec 13 '24 | Sell | $9.02 | 4,150 | $37,435.08 | 14,770 |
Latest Novavax Inc. News
NVAX Breaking Stock News: Dive into NVAX Ticker-Specific Updates for Smart Investing
Simply Wall St.
19 hours ago
Novavax, Inc. (NASDAQ:NVAX) About To Shift From Loss To Profit
Zacks
8 days ago
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know
Investor's Business Daily
11 days ago
Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots
Zacks
14 days ago
Wall Street Analysts Predict an 81.61% Upside in Novavax (NVAX): Here's What You Should Know
Zacks
14 days ago
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Insider Monkey
15 days ago
Novavax, Inc. (NVAX) Stock: The Under-the-Radar Stock Poised for Massive Upside in 2025
Investor's Business Daily
19 days ago
Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks
Zacks
20 days ago
Novavax (NVAX) Rises But Trails Market: What Investors Should Know
Compare NVAX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVAX Novavax Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.